Switzerland

Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus

Lead Product(s): mRNA-1273

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Moderna Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 01, 2020

Details:

Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Roche Drops Hep B Antiviral as Late-Stage Pipeline Tests Largely on Track' Despite COVID-19 Disruption

Lead Product(s): RG6217

Therapeutic Area: Infections and Infectious Diseases Product Name: RG6217

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 23, 2020

Details:

Roche has canned a phase 1 test of a potential hepatitis B antiviral as part of its third-quarter clean-up of unwanted pipeline drugs.

Virometix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million

Lead Product(s): V-306

Therapeutic Area: Infections and Infectious Diseases Product Name: V-306

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $8.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing July 16, 2020

Details:

The financing will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV, advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.

DNDi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

Lead Product(s): LXE408

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement February 25, 2020

Details:

Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials and DNDi will lead Phase II and Phase III development in India.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Lonza Group

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus

F. Hoffmann-La Roche

Roche Drops Hep B Antiviral as Late-Stage Pipeline Tests Largely on Track' Despite COVID-19 Disruption

Virometix

Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million

DNDi

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis